03:47 PM EST - Adherex Technologies, Inc. : announced that the Children's Oncology Group, posted top line results under Study ACCL0431, A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children. No statistical analysis was published and a full analysis of all secondary endpoints, including event free survival and overall survival, is pending. Information posted on the website is incomplete and final results may differ from those presented. Adherex Technologies, Inc.
shares T.AHX are trading down $0.02 at $0.93.
